Pablo Llerena
YOU?
Author Swipe
View article: 1088 Cancer immune checkpoint therapy efficacy and machine learning outcome predictions as stratified by smoking status and cancer type – a multi-national database study
1088 Cancer immune checkpoint therapy efficacy and machine learning outcome predictions as stratified by smoking status and cancer type – a multi-national database study Open
View article: Extracellular Matrix–MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC
Extracellular Matrix–MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC Open
Purpose: Immune checkpoint inhibitors (ICI) have demonstrated clinical benefit in head and neck squamous cell carcinoma (HNSCC); however, single-agent efficacy is limited, leaving significant unmet needs. Metformin may synergize with ICIs,…
View article: Supplementary Figure S2 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma
Supplementary Figure S2 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma Open
Supplementary Figure 2: Effect of IDO inhibitor BMS986205 on response rate and the tryptophan kynurenine pathway. A and B: IDO1 gene expression levels and tryptophan kynurenine pathway activity score, respectively, compared between baselin…
View article: Supplementary Figure S3 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma
Supplementary Figure S3 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma Open
Supplement Figure 3: Signature-based Biomarkers. A: Signature-Based biomarkers for HPV negative patients. B: Signature-based biomarkers for HPV positive patients. ‘Primary Path Response’ refers to analysis based on the pTR at the primary s…
View article: Supplementary Table S4 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma
Supplementary Table S4 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma Open
Supplement Table 4A-4B: The following is a comprehensive list of the top 20 functional enrichments in the B cell (A) and CAF2 (B) gene sets utilizing STRING database to analyze protein-protein interaction pairs among the leading edge.
View article: Supplementary Table S1 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma
Supplementary Table S1 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma Open
Supplement Table 1: Representativeness of Study Participants.
View article: Supplementary Figure S1 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma
Supplementary Figure S1 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma Open
Supplement Figure 1: Waterfall Plots. A: Degree of pathologic treatment response (pTR) at the lymph nodes. B: Degree of pathologic response at the primary site, stratifed by treatment arm. C: Degree of RECIST response of primary tumor site…
View article: Supplementary Table S3 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma
Supplementary Table S3 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma Open
Supplement Table. 3A-3C: Pro-B (A), Second Messenger (B), and CAF2 (C) leading edge genes unique to non-responders, shared between non-responders and responders, and unique to responders.
View article: Supplementary Figure S4 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma
Supplementary Figure S4 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma Open
Supplement Figure 4: STRING Networks enlarged. The STRING networks of B cell (A) and CAF (B) as visualized in Figure 5.
View article: Supplementary Table S2 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma
Supplementary Table S2 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma Open
Supplement Table 2A-2E: GSEA quantitative data for the B cell gene sets and CAF2 gene set for Post- vs Pre-treatments Responders vs Non responders. The following is a comprehensive list of supervised B-cell (A-C) and CAF (D-E) enrichment s…
View article: Supplementary Appendix S1 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma
Supplementary Appendix S1 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma Open
Supplementary Appendix
View article: Comprehensive Management of Obstructive Sleep Apnea With <scp>CPAP</scp> in a Surgical Otolaryngology Practice
Comprehensive Management of Obstructive Sleep Apnea With <span>CPAP</span> in a Surgical Otolaryngology Practice Open
Objective This study aims to investigate the medical management of obstructive sleep apnea ( OSA ) utilizing continuous positive airway pressure ( CPAP ) by the Otolaryngology departments within a tertiary care institution. Methods Data wa…
View article: Supplementary Figure S4 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma
Supplementary Figure S4 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma Open
Supplement Figure 4: STRING Networks enlarged. The STRING networks of B cell (A) and CAF (B) as visualized in Figure 5.
View article: Supplementary Appendix S1 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma
Supplementary Appendix S1 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma Open
Supplementary Appendix
View article: Supplementary Table S4 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma
Supplementary Table S4 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma Open
Supplement Table 4A-4B: The following is a comprehensive list of the top 20 functional enrichments in the B cell (A) and CAF2 (B) gene sets utilizing STRING database to analyze protein-protein interaction pairs among the leading edge.
View article: Data from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma
Data from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma Open
Purpose:We evaluated whether indoleamine 2,3-dioxygenase (IDO1) inhibitor (IDOi) BMS986205 + PD-1 inhibitor nivolumab enhanced T-cell activity and augmented immune-mediated antitumor responses in untreated, resectable head and neck squamou…
View article: Supplementary Figure S3 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma
Supplementary Figure S3 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma Open
Supplement Figure 3: Signature-based Biomarkers. A: Signature-Based biomarkers for HPV negative patients. B: Signature-based biomarkers for HPV positive patients. ‘Primary Path Response’ refers to analysis based on the pTR at the primary s…
View article: Supplementary Figure S2 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma
Supplementary Figure S2 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma Open
Supplementary Figure 2: Effect of IDO inhibitor BMS986205 on response rate and the tryptophan kynurenine pathway. A and B: IDO1 gene expression levels and tryptophan kynurenine pathway activity score, respectively, compared between baselin…
View article: Supplementary Table S3 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma
Supplementary Table S3 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma Open
Supplement Table. 3A-3C: Pro-B (A), Second Messenger (B), and CAF2 (C) leading edge genes unique to non-responders, shared between non-responders and responders, and unique to responders.
View article: Supplementary Figure S1 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma
Supplementary Figure S1 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma Open
Supplement Figure 1: Waterfall Plots. A: Degree of pathologic treatment response (pTR) at the lymph nodes. B: Degree of pathologic response at the primary site, stratifed by treatment arm. C: Degree of RECIST response of primary tumor site…
View article: Supplementary Table S1 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma
Supplementary Table S1 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma Open
Supplement Table 1: Representativeness of Study Participants.
View article: Supplementary Table S2 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma
Supplementary Table S2 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma Open
Supplement Table 2A-2E: GSEA quantitative data for the B cell gene sets and CAF2 gene set for Post- vs Pre-treatments Responders vs Non responders. The following is a comprehensive list of supervised B-cell (A-C) and CAF (D-E) enrichment s…
View article: Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma
Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma Open
Purpose: We evaluated whether indoleamine 2,3-dioxygenase (IDO1) inhibitor (IDOi) BMS986205 + PD-1 inhibitor nivolumab enhanced T-cell activity and augmented immune-mediated antitumor responses in untreated, resectable head and neck squamo…
View article: 599 Impact of metformin on immune activity in head and neck squamous cell carcinoma (HNSCC)
599 Impact of metformin on immune activity in head and neck squamous cell carcinoma (HNSCC) Open
View article: 27 Evaluating the impact of age on biomarkers for and efficacy of neoadjuvant immune checkpoint inhibitor therapy for head and neck squamous cell carcinoma
27 Evaluating the impact of age on biomarkers for and efficacy of neoadjuvant immune checkpoint inhibitor therapy for head and neck squamous cell carcinoma Open
View article: 600 Differential gene enrichment in response to durvalumab and metformin in head and neck cancer patients: the role of the neutrophil to lymphocyte ratio (NLR) and epithelial mesenchymal transition (EMT)
600 Differential gene enrichment in response to durvalumab and metformin in head and neck cancer patients: the role of the neutrophil to lymphocyte ratio (NLR) and epithelial mesenchymal transition (EMT) Open
View article: Obesity and Survival After Immune Checkpoint Inhibition for Head and Neck Squamous Cell Carcinoma
Obesity and Survival After Immune Checkpoint Inhibition for Head and Neck Squamous Cell Carcinoma Open
Importance For patients treated with immune checkpoint inhibitors (ICIs), recent data suggest that obesity has a beneficial effect on survival outcomes in various cancer types. Reports on this association in head and neck cancer are limite…
View article: Prognostic Value of Routine Blood Markers in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
Prognostic Value of Routine Blood Markers in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) Open
PURPOSE The levels of inflammatory blood markers, such as neutrophils, platelets, monocytes, and lymphocytes, can be informative for several cancer prognoses. However, the changes in other blood markers may be additional sources of prognos…
View article: Neoadjuvant Nivolumab Plus Carboplatin and Paclitaxel in Patients with Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck: A Phase II, Single-Arm Trial
Neoadjuvant Nivolumab Plus Carboplatin and Paclitaxel in Patients with Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck: A Phase II, Single-Arm Trial Open
View article: Perioperative Outcomes in Patients Who Underwent Fibula, Osteocutaneous Radial Forearm, and Scapula Free Flaps
Perioperative Outcomes in Patients Who Underwent Fibula, Osteocutaneous Radial Forearm, and Scapula Free Flaps Open
Importance Studies comparing perioperative outcomes of fibula free flaps (FFFs), osteocutaneous radial forearm free flaps (OCRFFFs), and scapula free flaps (SFFs) have been limited by insufficient sample size. Objective To compare the peri…